Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has demonstrated positive clinical outcomes for its investigational small molecule RAP-219 in a Phase 2 proof-of-concept study, showing significant reductions in long episodes and clinical seizures with improvements in patient daily functioning. The favorable reception of RAP-219 at the AES conference indicates strong physician enthusiasm for new therapies and an evolving reimbursement landscape for branded antiepileptic medications, which could enhance market opportunities among early-line focal onset seizure patients. Additionally, the promising results of RAP-219, particularly regarding its potential applicability to generalized seizures, contribute to a strong foundation for the company's growth prospects in the burgeoning field of neurological and psychiatric disorder treatments.

Bears say

Rapport Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, including uncertainty regarding the clinical success of its pipeline products and intense competition from more advanced therapies in the market. The company's flagship candidate, RAP-219, could experience lower commercial adoption, compounded by the possibility of manufacturing delays in drug development and approval processes. Additionally, the reliance on external funding to advance its clinical trials raises concerns about financial stability and the ability to sustain operations amid potential regulatory hurdles and trial execution challenges.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.